ILD Associated With More Muscle Mass, Less Bone Density Loss
Researchers of the study aimed to determine the differences in muscle area and bone density in patients with end-stage lung disease.
Interstitial Lung Disease
Nintedanib Granted Breakthrough Therapy for Progressive Fibrosing Interstitial Lung Disease
The FDA has granted Breakthrough Therapy designation to nintedanib for the treatment of chronic fibrosing ILDs with a progressive phenotype.
Pirfenidone May Benefit Unclassifiable Progressive Fibrosing Interstitial Lung Disease
Although the planned statistical model could not be applied to primary end point data, key secondary end point analysis suggested that patients with progressive fibrosing unclassifiable interstitial lung disease could benefit from pirfenidone.
Nintedanib Associated With Lower Rate of FVC Decline in Interstitial Lung Disease
Nintedanib was linked to a lower rate of decline in forced vital capacity vs placebo in a phase 3 trial.
Plasma Biomarkers of Idiopathic Pulmonary Fibrosis May Predict Survival
Plasma biomarkers of progressive idiopathic pulmonary fibrosis may be markers of progressive pulmonary fibrosis regardless of the type of interstitial lung disease.
FDA Warns of Possible Interstitial Lung Disease, Pneumonitis With Certain Breast Cancer Drugs
Healthcare professionals are being advised to monitor patients regularly for pulmonary symptoms indicative of ILD and/or pneumonitis, including hypoxia, cough, dyspnea, and interstitial infiltrates on radiologic exams.
FDA Approves Treatment for Systemic Sclerosis-Associated Interstitial Lung Disease
The FDA has approved Ofev capsules as the first FDA-approved treatment to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD.
RV to LV Diameter Ratio May Predict Mortality in Interstitial Lung Disease
An increased right to left ventricle diameter ratio may help identify high-risk patients with suspected interstitial lung disease/pulmonary hypertension.
FDA Panel Votes on Nintedanib for Systemic Sclerosis Associated Interstitial Lung Disease
The FDA Arthritis Advisory Committee voted 10 to 7 in favor of approval of Ofev for the treatment of systemic sclerosis associated with interstitial lung disease.
Azathioprine and Mycophenolate Mofetil May Benefit Myositis-Related ILD
In patients with myositis-related interstitial lung disease, azathioprine and mycophenolate mofetil treatment offers clinical improvements and a reduction in prednisone dose.
Next post in Restrictive Lung Disease
